Table 1:
Matched features of tumors that recurred (cases) vs. non-recurrent tumors (controls)
Variable | Categories | Case (n=50) | Control (n=50*) | P-value |
---|---|---|---|---|
| ||||
Overall pathologic stage | Stage I | 25 | 25 | 1.000 |
Stage II | 25 | 25 | ||
| ||||
Pathologic T-stage | pT0 | 1 | 0 | .483 |
pT1 | 11 | 15 | ||
pT2 | 32 | 28 | ||
pT3 | 6 | 7 | ||
| ||||
Pathologic N-stage | pN0 | 5 | 5 | .977 |
pN1 | 26 | 27 | ||
pN2 | 19 | 18 | ||
| ||||
Treatment | Surgery | 4 | 4 | 1.000 |
Surgery + RT | 19 | 19 | ||
Surgery + CRT | 27 | 27 | ||
| ||||
Systemic agent | Cisplatin | 21 | 23 | .848 |
Cetuximab | 5 | 3 | ||
Carboplatin/Taxol | 1 | 1 | ||
| ||||
Smoking history | ≤10 pack-years | 34 | 33 | .832 |
>10 pack-years | 16 | 17 |
RT=radiation therapy, CRT=chemoradiation, P-values are from Fisher-exact test. Freeman-Holton extension was used for more than two categories.
Comparison includes duplication of one control as a match for two cases